We know that many health conditions have underlying chronic inflammation that can make disease management and treatment more complex. Inflammatory bowel conditions, such as IBD or Crohn’s Disease are closely related to inflammation.
In this short video with Dr. Serhan of Harvard Medical School, Metagenics Institute inquires about the opportunities to treat IBD and Crohn’s Disease with SPMs for resolution of inflammation.
In animal models, there are encouraging result on three resolvins: D1; Mar1; and E1. Each of these is able to reduce pro-inflammatory mediators to preserve GI integrity and maintain gut barrier function. Rigorously testing their efficacy in reducing IBD is the next step for determining clinical application.
14. Insights from the Metagenics Lifestyle Summit 2015 in Phoenix, AZ: Charles Serhan, PhD
